Metraipolis › archive › dc_84f43aa4ee67

Safety and Clinical Outcome of Bleomycin-Electrosclerotherapy (BEST) Treating Lymphatic Malformations (LMs) — Europe PMC PMID:40903646

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40903646
DOI
10.1007/s00270-[numero omesso]-6
License (as archived)
solo-consultazione
Archived
2026-11-10T03:18:29.549Z
SHA-256 of the archived text
c225fe366237860191ebb2c3ed526bc4daa0af37d137be567d03df50bb5c21aa
Stable URL of this page
https://metraipolis.com/documento/dc_84f43aa4ee67

How to cite

Safety and Clinical Outcome of Bleomycin-Electrosclerotherapy (BEST) Treating Lymphatic Malformations (LMs) — Europe PMC PMID:40903646 — Europe PMC (en), https://europepmc.org/article/MED/40903646 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_84f43aa4ee67 (Metraipolis archive dc_84f43aa4ee67, sha256 c225fe366237860191ebb2c3ed526bc4daa0af37d137be567d03df50bb5c21aa)
BibTeX
@misc{dc84f43aa4ee67,
  title = {Safety and Clinical Outcome of Bleomycin-Electrosclerotherapy (BEST) Treating Lymphatic Malformations (LMs) — Europe PMC PMID:40903646},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40903646},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_84f43aa4ee67; sha256 c225fe366237860191ebb2c3ed526bc4daa0af37d137be567d03df50bb5c21aa},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40903646. Agents can read the archived copy with the MCP tool read_document.